semaglutide and osa Survey: Providers Want GLP-1s Approved for Sleep Apnea What if the future of

Can semaglutide (glucagon-like peptide-1 receptor agonist) lead to allodynia?

Prospective randomized controlled trials are needed to evaluate larger cohorts of patients to determine if semaglutide once-weekly may close the gap between lifestyle intervention and revision surgery to treat weight recidivism or insufficient weight loss after BS

Semaglutide therapy provides a medically supervised, science-backed approach to weight management, supporting appetite control, metabolic health, and sustainable results

A landmark randomized, double-blind, placebo-controlled Phase 2 study conducted in the United States enrolled 338 adults with obesity or overweight conditions across multiple dosing regimens

Overcoming obesity and health conditions associated with obesity (co-morbidities) can be a constant, daily struggle